Cancer cell membrane-wrapped nanoparticles for cancer immunotherapy: A review of current developments
BackgroundAs the forefront of nanomedicine, bionic nanotechnology has been widely used for drug delivery in order to obtain better efficacy but less toxicity for cancer treatments. With the rise of immunotherapy, the combination of nanotechnology and immunotherapy will play a greater potential of an...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-08-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.973601/full |
| _version_ | 1817996173723566080 |
|---|---|
| author | Qi Jiang Mixue Xie Ruyin Chen Feifei Yan Chanqi Ye Qiong Li Shuaishuai Xu Wei Wu Yunlu Jia Peng Shen Jian Ruan |
| author_facet | Qi Jiang Mixue Xie Ruyin Chen Feifei Yan Chanqi Ye Qiong Li Shuaishuai Xu Wei Wu Yunlu Jia Peng Shen Jian Ruan |
| author_sort | Qi Jiang |
| collection | DOAJ |
| description | BackgroundAs the forefront of nanomedicine, bionic nanotechnology has been widely used for drug delivery in order to obtain better efficacy but less toxicity for cancer treatments. With the rise of immunotherapy, the combination of nanotechnology and immunotherapy will play a greater potential of anti-tumor therapy. Due to its advantage of homologous targeting and antigen library from source cells, cancer cell membrane (CCM)-wrapped nanoparticles (CCNPs) has become an emerging topic in the field of immunotherapy.Key scientific concepts of reviewCCNP strategies include targeting or modulating the tumor immune microenvironment and combination therapy with immune checkpoint inhibitors and cancer vaccines. This review summarizes the current developments in CCNPs for cancer immunotherapy and provides insight into the challenges of transferring this technology from the laboratory to the clinic as well as the potential future of this technology.ConclusionThis review described CCNPs have enormous potential in cancer immunotherapy, but there are still challenges in terms of translating their effects in vitro to the clinical setting. We believe that these challenges can be addressed in the future with a focus on individualized treatment with CCNPs as well as CCNPs combined with other effective treatments. |
| first_indexed | 2024-04-14T02:18:18Z |
| format | Article |
| id | doaj.art-04eeee594bd640f0b9e9fe733b203c12 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-14T02:18:18Z |
| publishDate | 2022-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-04eeee594bd640f0b9e9fe733b203c122022-12-22T02:18:07ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-08-011310.3389/fimmu.2022.973601973601Cancer cell membrane-wrapped nanoparticles for cancer immunotherapy: A review of current developmentsQi Jiang0Mixue Xie1Ruyin Chen2Feifei Yan3Chanqi Ye4Qiong Li5Shuaishuai Xu6Wei Wu7Yunlu Jia8Peng Shen9Jian Ruan10Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, and Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, Hangzhou, ChinaDepartment of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaDepartment of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, and Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, Hangzhou, ChinaDepartment of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, and Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, Hangzhou, ChinaDepartment of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, and Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, Hangzhou, ChinaDepartment of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, and Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, Hangzhou, ChinaDepartment of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, and Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, Hangzhou, ChinaDepartment of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, and Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, Hangzhou, ChinaDepartment of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, and Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, Hangzhou, ChinaDepartment of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, and Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, Hangzhou, ChinaDepartment of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, and Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, Hangzhou, ChinaBackgroundAs the forefront of nanomedicine, bionic nanotechnology has been widely used for drug delivery in order to obtain better efficacy but less toxicity for cancer treatments. With the rise of immunotherapy, the combination of nanotechnology and immunotherapy will play a greater potential of anti-tumor therapy. Due to its advantage of homologous targeting and antigen library from source cells, cancer cell membrane (CCM)-wrapped nanoparticles (CCNPs) has become an emerging topic in the field of immunotherapy.Key scientific concepts of reviewCCNP strategies include targeting or modulating the tumor immune microenvironment and combination therapy with immune checkpoint inhibitors and cancer vaccines. This review summarizes the current developments in CCNPs for cancer immunotherapy and provides insight into the challenges of transferring this technology from the laboratory to the clinic as well as the potential future of this technology.ConclusionThis review described CCNPs have enormous potential in cancer immunotherapy, but there are still challenges in terms of translating their effects in vitro to the clinical setting. We believe that these challenges can be addressed in the future with a focus on individualized treatment with CCNPs as well as CCNPs combined with other effective treatments.https://www.frontiersin.org/articles/10.3389/fimmu.2022.973601/fullcancer cell membranemembrane-wrappednanoparticledrug deliveryimmunotherapynanovaccine |
| spellingShingle | Qi Jiang Mixue Xie Ruyin Chen Feifei Yan Chanqi Ye Qiong Li Shuaishuai Xu Wei Wu Yunlu Jia Peng Shen Jian Ruan Cancer cell membrane-wrapped nanoparticles for cancer immunotherapy: A review of current developments Frontiers in Immunology cancer cell membrane membrane-wrapped nanoparticle drug delivery immunotherapy nanovaccine |
| title | Cancer cell membrane-wrapped nanoparticles for cancer immunotherapy: A review of current developments |
| title_full | Cancer cell membrane-wrapped nanoparticles for cancer immunotherapy: A review of current developments |
| title_fullStr | Cancer cell membrane-wrapped nanoparticles for cancer immunotherapy: A review of current developments |
| title_full_unstemmed | Cancer cell membrane-wrapped nanoparticles for cancer immunotherapy: A review of current developments |
| title_short | Cancer cell membrane-wrapped nanoparticles for cancer immunotherapy: A review of current developments |
| title_sort | cancer cell membrane wrapped nanoparticles for cancer immunotherapy a review of current developments |
| topic | cancer cell membrane membrane-wrapped nanoparticle drug delivery immunotherapy nanovaccine |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.973601/full |
| work_keys_str_mv | AT qijiang cancercellmembranewrappednanoparticlesforcancerimmunotherapyareviewofcurrentdevelopments AT mixuexie cancercellmembranewrappednanoparticlesforcancerimmunotherapyareviewofcurrentdevelopments AT ruyinchen cancercellmembranewrappednanoparticlesforcancerimmunotherapyareviewofcurrentdevelopments AT feifeiyan cancercellmembranewrappednanoparticlesforcancerimmunotherapyareviewofcurrentdevelopments AT chanqiye cancercellmembranewrappednanoparticlesforcancerimmunotherapyareviewofcurrentdevelopments AT qiongli cancercellmembranewrappednanoparticlesforcancerimmunotherapyareviewofcurrentdevelopments AT shuaishuaixu cancercellmembranewrappednanoparticlesforcancerimmunotherapyareviewofcurrentdevelopments AT weiwu cancercellmembranewrappednanoparticlesforcancerimmunotherapyareviewofcurrentdevelopments AT yunlujia cancercellmembranewrappednanoparticlesforcancerimmunotherapyareviewofcurrentdevelopments AT pengshen cancercellmembranewrappednanoparticlesforcancerimmunotherapyareviewofcurrentdevelopments AT jianruan cancercellmembranewrappednanoparticlesforcancerimmunotherapyareviewofcurrentdevelopments |